Mosapride + domperidone
ApprovedUNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diabetic Gastroparesis
Conditions
Diabetic Gastroparesis
Trial Timeline
Oct 1, 2014 → Dec 1, 2015
NCT ID
NCT02264587About Mosapride + domperidone
Mosapride + domperidone is a approved stage product being developed by Sumitomo Pharma for Diabetic Gastroparesis. The current trial status is unknown. This product is registered under clinical trial identifier NCT02264587. Target conditions include Diabetic Gastroparesis.
What happened to similar drugs?
20 of 20 similar drugs in Diabetic Gastroparesis were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02264587 | Approved | UNKNOWN |
Competing Products
20 competing products in Diabetic Gastroparesis